Physician profile
Brian R Sinclair
NPI 1013901594
$3,633.45
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,718 · 2020: $1,832 · 2021: $82.84.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $720.74 | 2019-2020 | |
| Glaxosmithkline, LLC. | $622.63 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $572.41 | 2019-2020 | |
| Grifols USA, LLC | $329.32 | 2019-2020 | |
| Genzyme Corporation | $199.06 | 2019-2020 | |
| Philips North America LLC | $176.82 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $123.35 | 2019-2020 | |
| Electromed, INC. | $113.39 | 2019-2021 | |
| Mylan Specialty L.P. | $108.62 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $81.60 | 2019-2020 | |
| Shire North American Group INC | $75.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $73.43 | 2019-2020 | |
| Eisai INC. | $67.46 | 2020 | |
| United Therapeutics Corporation | $53.56 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.49 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $49.82 | 2019-2020 | |
| Genentech USA, INC. | $48.06 | 2019-2020 | |
| Gilead Sciences, INC. | $36.46 | 2019 | |
| Merck Sharp & Dohme LLC | $32.89 | 2019 | |
| Insmed, INC. | $29.03 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $19.87 | 2019 | |
| Melinta Therapeutics, LLC | $17.79 | 2020 | |
| Covidien Lp | $16.97 | 2019 | |
| Allergan, INC. | $13.89 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.